A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

• ClinicalTrials.gov Identifier: NCT04209179
• Recruitment Status: Recruiting
• First Posted: December 24, 2019
• Last Update Posted: October 22, 2020
• Sponsor: Chugai Pharmaceutical
• Information provided by (Responsible Party): Chugai Pharmaceutical

Study Description

Brief Summary:

This is a multi-center, placebo-controlled, randomized, double-blind, multiple-ascending dose study in patients with hypoparathyroidism.

The total duration of study medication treatment will be 13 weeks and includes a Fixed-Dose Treatment period and a Dose Titration Treatment period. The Fixed-Dose Treatment period consists of multiple daily dosing at a fixed dose level. Once patients have completed the Fixed-Dose Treatment period, patients will enter the Dose Titration Treatment period where PCO371 (or placebo), oral calcium and oral active vitamin D can each be titrated according to the patient's albumin-corrected serum calcium level.

Condition or disease	Intervention/treatment	Phase
Hypoparathyroidism	Drug: PCO371; Drug: Placebo	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism
• Actual Study Start Date: July 23, 2020
• Estimated Primary Completion Date: May 31, 2021
• Estimated Study Completion Date: May 31, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: PCO371 Low Dose and Low administration frequency; PCO371 low dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).	Drug: PCO371; PCO371 capsule
Experimental: PCO371 High Dose and Low administration frequency; PCO371 high dose and low administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).	Drug: PCO371; PCO371 capsule
Experimental: PCO371 High Dose and High administration frequency; PCO371 high dose and high administration frequency by oral administration for the first period ( Fixed-Dose treatment period). PCO371 will be titrated in the following period (Dose Titration Treatment period).	Drug: PCO371; PCO371 capsule
Placebo Comparator: Placebo; Placebo by oral administration.	Drug: Placebo; Placebo capsule

Outcome Measures

Primary Outcome Measures :

1. Treatment-emergent adverse events [ Time Frame: 13 weeks ]
   Treatment-emergent adverse events (TEAEs) will be assessed including the number and rate of TEAEs.
2. Selected adverse events [ Time Frame: 13 weeks ]
   Hypercalcemia and hypocalcemia will be assessed including the number and rate of these.
3. Clinically significant change in the safety parameters; vital signs [ Time Frame: 13 weeks ]
   Abnormal change in vital signs.
4. Clinically significant change in the safety parameters; body weight [ Time Frame: 13 weeks ]
   Abnormal change in body weight.
5. Clinically significant change in the safety parameters; physical examination findings [ Time Frame: 13 weeks ]
   Abnormal change in physical examination findings.
6. Clinically significant change in the safety parameters; laboratory test value [ Time Frame: 13 weeks ]
   Abnormal change in laboratory test value including hematology, biochemistry, coagulation, urinalysis.
7. Clinically significant change in the safety parameters; electrocardiogram results [ Time Frame: 13 weeks ]
   Abnormal change in electrocardiogram results including PQ (PR), RR, QRS, QT, pulse, QTcB, QTcF and ECG abnormalities.

Secondary Outcome Measures :

1. Pharmacokinetic data of PCO371; Plasma concentrations of PCO371 [ Time Frame: 13 weeks ]
   Plasma concentrations versus time data
2. Pharmacokinetic data of PCO371; AUC0-last [ Time Frame: 13 weeks ]
   AUC0-last of PCO371
3. Pharmacokinetic data of PCO371; Cmax of PCO371 [ Time Frame: 13 weeks ]
   Cmax of PCO371
4. Pharmacokinetic data of PCO371; Tmax of PCO371 [ Time Frame: 13 weeks ]
   Tmax of PCO371
5. Pharmacokinetic data of PCO371; T1/2 of PCO371 [ Time Frame: 13 weeks ]
   T1/2 of PCO371
6. Pharmacodynamic data in serum or plasma [ Time Frame: 13 weeks ]
   Time profile of serum/plasma concentrations in albumin corrected total calcium (Ca), 25 hydroxy vitamin D, 1,25-dihydroxy vitamin D, phosphate, magnesium, and cAMP
7. Pharmacodynamic data in urine [ Time Frame: 13 weeks ]
   Urinary excretion of Ca, phosphate, magnesium, protein, sodium, potassium, chloride, and cAMP (via 24-hour urine collection)
8. Pharmacodynamic data; nephrogenous cAMP concentration [ Time Frame: 13 weeks ]
   Time profile of nephrogenous cAMP concentration
9. Pharmacodynamic data; bone turnover markers in serum or plasma [ Time Frame: 13 weeks ]
   Time profile of serum/plasma concentrations in bone turnover markers (i.e. bone-specific alkaline phosphatase, type 1 pro-collagen amino-terminal peptide, C-terminal telopeptide of type 1 collagen, and osteocalcin)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Able and willing to provide written informed consent, to use the device for PRO and electronic diary and to comply with the requirements of the protocol.
2. Adult males or females ≥18 years of age
3. History of hypoparathyroidism for more than 1-year post initial diagnosis
4. PTH level is inappropriately low
5. Dose of thyroid replacement therapy must have been stable for ≥3 months prior to first dose if receiving thyroid replacement therapy
6. Receiving treatment with active vitamin D therapy (calcitriol ≥0.25 μg/day or alfacalcidol ≥0.5 μg/day)
7. Receiving Oral calcium treatment (≥1000 mg/day)
8. No significant changes in the diet from 4 weeks prior to Screening and for the duration of the study.
9. Fasting albumin-corrected serum calcium concentration between 8.0 and 9.0 mg/dL at 2 consecutive visits during the Run-In period, and no more than 25% change in daily doses of oral Ca and active vitamin D between the 2 consecutive visits during the Run-In period.
10. On Day 1, fasting albumin-corrected serum calcium level between 7.5 and 9.0 mg/dL
11. Serum magnesium level ≥ lower limit of normal and ≤ 1.2 x laboratory upper limit of normal
12. Serum 25[OH] vitamin D level within the laboratory normal range
13. Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2
14. Women of childbearing potential must have a negative highly sensitive urine or serum pregnancy test result
15. For women of childbearing potential: agreement to use a highly effective contraceptive method during the treatment period and for 28 days after the last dose of study drug. Hormonal contraceptive methods must be supplemented by a barrier method (preferably male condom) and agreement to refrain from egg donation during the treatment period and for 28 days after the last dose of study drug.
16. For men: agreement to remain abstinent or use contraceptive measures. Men must refrain from donating sperm during this same period.
17. Ability to comply with the study protocol, in the investigator's judgment.
18. For Canadian sites only: Ferritin, as assessed by the local laboratory at screening, must be ≥ the lower limit of normal (LLN).

Exclusion Criteria:

1. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the last dose of PCO371
2. Known or suspected history of hypoparathyroidism resulting from an activating mutation in the Ca-sensing receptor gene or impaired responsiveness to PTH (pseudohypoparathyroidism)
3. Clinically significant hypomagnesemia. Adequately treated hypomagnesemia is permitted
4. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism
5. History of a major bone fracture within 3 months prior to Screening
6. Any history of clinically significant bleeding disorder or clinically significant abnormal clotting times
7. History of thyroid cancer unless documented to be disease free for ≥1 year
8. History of any other cancer in the past 3 years from Screening with the exception of thyroid cancer , completely removed nonmelanoma skin cancer, basal cell skin carcinoma, and cancer in situ of the cervix
9. Dependence on monthly or more frequent parenteral calcium infusions to maintain calcium homeostasis
10. Disease processes that may adversely affect gastrointestinal absorption
11. Use of oral bisphosphonates within 6 months of Screening and/or intravenous bisphosphonate preparations within 12 months of Screening. Any use of zoledronic acid prior to Screening.
12. Use of other drugs known to influence calcium and bone metabolism such as calcitonin, fluoride tablets or cinacalcet hydrochloride within 4 weeks prior to Screening.
13. Patients who have taken inducers of CYP3A4, Pgp,or BCRP within 1 month before IMP administration or taken inhibitors of CYP3A4, P-gp, or BCRP within 2 weeks before IMP administration (or either 6 times the t1/2 of the drugs mentioned above, whichever is longer).
14. Use of loop or thiazide diuretics within 14 days prior to first dose of IMP
15. Use of anti-coagulants, anti-platelet medications, and aspirin within 2 weeks (or within 6 times the t1/2 of the drug mentioned above, whichever is longer) prior to IMP administration
16. Use of proton pump inhibitors or H2 blockers within 48 hours prior to the first dose of IMP and antacids within 4 hours prior to the first dose of IMP.
17. History of radiotherapy to the skeleton within 5 years
18. Presence of open epiphyses at the distal radius and ulna as well as carpals, metacarpals, phalanges, and pelvis
19. ALT, AST, or ALP > 2.5 × ULN at Screening
20. Patients with documented active HBV, active HCV infection or any other known active virus infection considered to be clinically relevant by the investigator.
21. Evidence of active alcohol, drug, or other substance abuse or addiction
22. History of a seizure that is unrelated to hypocalcemia within 6 months prior to Screening
23. Insulin dependent diabetes mellitus or poorly controlled Type II diabetes mellitus (defined as hemoglobin A1c [HbA1c] >8%)
24. Chronic/severe cardiac disease
25. Active gout or history of active gout within 6 months prior to first dose of study medication
26. History of clinically significant cognitive deficit that would, at the discretion of the investigator, interfere with a patient's ability to participate in the trial.
27. Any disease or condition that, in the opinion of the investigator, has a high probability of precluding the patient from completing the study or where the patient could not or would not appropriately comply with study requirements
28. Participation in any clinical trials or has taken any IMP (including placebo) either within 2 months or 5 times the t1/2 of the IMP, whichever is longer, prior to first dose of IMP for this study
29. Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34) or other Nterminal fragments or analogs of PTH or PTH-related proteins within 2 months or 5 times the t1/2 of the treatment (whichever is longer) prior to Screening.
30. Patients with hypersensitivity to PCO371 or to any component of this drug product

Contacts and Locations

Contacts

Contact: Clinical trials information; only use Email; clinical-trials@chugai-pharm.co.jp

Locations

United States, California

The Lundquist Institute; Recruiting

Torrance, California, United States, 90502

Contact: Xianodan Han 310-222-1865 xhan@lundquist.org

Principal Investigator: Ronald Swerdloff, MD

United States, Illinois

University of Chicago; Not yet recruiting

Chicago, Illinois, United States, 60637

Contact: Meredith M Bartolomei, MS 773-702-1197 mbartolomei@medicine.bsd.uchicago.edu

Principal Investigator: Tamara Vokes, MD

United States, Indiana

Indiana University School of Medicine; Recruiting

Indianapolis, Indiana, United States, 46202

Contact: Marian D Hart, BSN, RN 317-948-8346 marihart@iu.edu

Principal Investigator: Erik A Imel, MD

United States, Kentucky

University of Kentucky; Recruiting

Lexington, Kentucky, United States, 40536

United States, Massachusetts

Massachusetts General Hospital; Recruiting

Boston, Massachusetts, United States, 02114

Contact: Taisha V Joseph, BS 617-643-2087 tjoseph6@mgh.harvard.edu

Principal Investigator: Michael Mannstadt, MD

United States, Minnesota

Mayo Clinic; Recruiting

Rochester, Minnesota, United States, 55905

Contact: Tami M Roberson 507-255-8621 Roberson.tamera@mayo.edu

Principal Investigator: Bart L Clarke, MD

United States, Ohio

Ohio State University Wexner Medical Center; Recruiting

Columbus, Ohio, United States, 43210

Contact: Amber R Anaya, MS, CCRC 614-688-6257 Amber.anaya@osumc.edu

Principal Investigator: Steven Ing

United States, Pennsylvania

Thomas Jefferson University; Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contact: Marsha Simmons, BS CCRP 215-955-1978 Marsha.simmons@jefferson.edu

Principal Investigator: Intekhab Ahmed, MD

Canada, CAN

Endocrinologie et néphrologie Centre de recherche du CHU de Québec; Recruiting

Québec, CAN, Canada, G1V 4G2

Contact: Sarah Chouinard-Castonguay +1 (418) 525-4444 ext 48729 Sarah.chouinard-castonguay@crchudequebec.ulaval.ca

Principal Investigator: Claudia Gagnon, MD

Canada, ONT

McMaster University Bone Research & Education Centre; Recruiting

Oakville, ONT, Canada, L6M 1M1

Contact: Aliya A Khan, MD, FRCPC (905) 844-5677

Principal Investigator: Aliya A Khan, MD, FRCPC

Hungary

Semmelweis Egyetem, Általános Orvostudományi Kar, Belgyógyászati és Onkológiai Klinika; Recruiting

Budapest, HU, Hungary, 1083

Sponsors and Collaborators

Chugai Pharmaceutical

Investigators

• Study Director: Sponsor Chugai Pharmaceutical Co. Ltd; clinical-trials@chugai-pharm.co.jp

More Information

• Responsible Party: Chugai Pharmaceutical
• ClinicalTrials.gov Identifier: NCT04209179
• Other Study ID Numbers: PCO104UG
• First Posted: December 24, 2019
• Last Update Posted: October 22, 2020
• Last Verified: October 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Hypoparathyroidism; Parathyroid Diseases; Endocrine System Diseases